Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Miami Beach, Florida Clinical Trials

A listing of Miami Beach, Florida clinical trials actively recruiting patient volunteers.

RESULTS

Found (170) clinical trials

A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus

The study consists of four phases: 4-week Screening Phase 24-week placebo-controlled phase Subjects will receive either 0.45 mg QD, 0.3 mg QD, 0.15 mg QD or placebo for the first 24 weeks of treatment. 28-week active treatment phase At Week 24, all subjects on placebo will be re-randomized to active ...

Phase

4.56 miles

Learn More »

Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Ulcerative Colitis

The primary objective of this study is to evaluate the testicular safety of filgotinib in adult males with moderately to severely active ulcerative colitis.

Phase

4.56 miles

Learn More »

Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer

This study is a randomized, double-blind, placebo-controlled international phase 2 trial in patients with HRG+, HR+, HER2- metastatic breast cancer that has progressed following treatment with no more than 2 prior therapies, one of which must have been a CDK inhibitor. All patients will be screened for heregulin using central ...

Phase

4.56 miles

Learn More »

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

This is an open-label, multicenter trial to collect long-term safety and efficacy data and to provide ongoing access to tisotumab vedotin for patients with solid tumors who have completed a tisotumab vedotin base trial.

Phase

4.56 miles

Learn More »

Phase 2a Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

A Phase 2a, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Study To Evaluate Safety, Tolerability, And Pharmacodynamics Of PF-05221304 Administered Daily For 16-weeks To Adult Subjects With Nonalcoholic Fatty Liver Disease

Phase

4.56 miles

Learn More »

Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma

Patients with cutaneous T cell lymphoma experience refractory and progressive disease despite current treatment, necessitating chronic disease management. In addition, there needs to be greater emphasis on combination treatment, which correlates with increased response rate, more rapid onset of response, and decreased side effect profile compared to monotherapy. The goal ...

Phase

4.56 miles

Learn More »

Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

This is a multicenter, randomized, double-masked, parallel group, placebo-controlled study evaluating the effects of ALK-001 administered daily by mouth in subjects with Stargardt disease (ABCA4-related). Stargardt disease is a rare genetic disorder that leads to damage to the retina and results in legal blindness. The onset of symptoms usually occurs ...

Phase

4.56 miles

Learn More »

IBP-9414 for the Prevention of Necrotizing Enterocolitis

Two different dose levels will be evaluated in two different birth weight categories, compared to placebo with regards to safety and tolerability.

Phase

4.56 miles

Learn More »

Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA

The primary objective of this study is to evaluate the safety and tolerability of lucinactant for inhalation, administered as an aerosolized dose in up to four escalating doses to preterm neonates 26 to 28 weeks gestational age who are receiving nasal continuous positive airway pressure (nCPAP) for respiratory distress syndrome ...

Phase

4.56 miles

Learn More »

Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

The purpose of this study is evaluate if abatacept is effective and safe in decreasing the level of protein loss in the urine in patients with excessive loss of protein in the urine (nephrotic syndrome) due to either focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD). Candidates must have ...

Phase

4.56 miles

Learn More »